PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.40 -0.01 (-1.63%)
As of: Oct 1, 2026 · 3:59 PM EDT

PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2026)

Updated

PharmaCyte Biotech (PMCB) reported Receivables - Accured of $188,384 for fiscal Q1 2027 (quarter ended Jul 31, 2026), down 11.3% from $212,500 a year earlier and down 21.8% from the prior quarter.

Analysis

PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Apr 30, 2026), PharmaCyte Biotech posted Receivables - Accured of $240,766, up 75.1% from FY2025.

  • By fiscal year, Receivables - Accured came in at $137,500 in FY2025 (unchanged) and $137,500 in FY2024.
  • The fiscal Q1 2027 figure ranks as the lowest quarterly Receivables - Accured since fiscal Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables - Accured (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 PharmaCyte Biotech 4.40 Mn 4.40 Mn - 188,384.00
Historic Data

Historic Data

Download Data
DateValue
Jul 31, 2026 188,384.00
Apr 30, 2026 240,766.00
Oct 31, 2025 287,500.00
Jul 31, 2025 212,500.00
Apr 30, 2025 137,500.00
Apr 30, 2024 137,500.00
API Access

PharmaCyte Biotech Receivables - Accured API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-accured&ticker=PMCB&period=max&api_key=YOUR_API_KEY